Biomerica, Inc. (BMRA) Stock

Biomerica, Inc. (BMRA) is a Healthcare stock trading at $2.19 (as of 2026-09-02), with a market capitalization of $10.05M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Understand Biomerica, Inc.: how it makes money

Biomerica develops and sells point-of-care diagnostic test kits that analyze blood, urine, or stool samples to detect diseases and measure biological markers in patients. It remains a micro-cap developer still seeking commercial scale, with a portfolio spanning multiple medical conditions sold primarily to the independent testing market.

Test-kit revenue is far too small to carry the fixed R&D and administrative overhead a small-cap diagnostics developer must fund, so every dollar of product sales still arrives before the company has paid its operating bill.

Business quality (Unprofitable): Unprofitable: the company cannot cover its own operating costs at the current revenue level and has no visible inflection in the latest quarter.

Bull case

Product cost near breakeven: Gross margin at -4% tells you the manufacture and supply of the kits almost covers the cost of goods; the loss is concentrated in fixed overhead and R&D, not in the product itself. If sales volume grows, the variable-cost side does not impose a further drag.

Bear case

Operating burn exceeds revenue: Operating margin of -132% means the company destroys roughly $1.32 in operating costs for every $1 of sales. At this scale there is no self-funding path; survival depends entirely on outside capital.
No topline base to scale from: The gross margin sits at -4% while revenue is negligible and declining, so even a collection of positive-gross-margin products would not yet offset the fixed-cost structure. The company needs both a volume inflection and a cost reset before profitability becomes realistic.

Valuation — source: SEC EDGAR (first-party)
Price	$2.19
Market Cap	$10.05M
Price / Book	3.82
Price / Sales	2.26

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.45M
Net Margin	-84.8%
Revenue Growth (YoY)	17.0%
EPS Growth (YoY)	-40.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	-12.09 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	GEODE CAPITAL MANAGEMENT, LLC ($118256.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Zackary S. Irani
Employees	64
Country	US
IPO Date	1984-09-07

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-09-02.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.